63
Views
4
CrossRef citations to date
0
Altmetric
Original Research

The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency

, , , , , , , , , , , , , & show all
Pages 687-696 | Published online: 28 Sep 2012

References

  • SeersholmNKok-JensenAClinical features and prognosis of life time non-smokers with severe alpha 1-antitrypsin deficiencyThorax19985342652689741368
  • JanciauskieneSErikssonSCalleaFDifferential detection of PAS-positive inclusions formed by the Z, Siiyama, and Mmalton variants of alpha1-antitrypsinHepatology20044051203121015486938
  • JanciauskieneSMBalsRKoczullaRVogelmeierCKohnleinTWelteTThe discovery of ?1-antitrypsin and its role in health and diseaseRespir Med201110581129113921367592
  • MahadevaRAtkinsonCLiZPolymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivoAm J Pathol2005166237738615681822
  • ParmarJSMahadevaRReedBJPolymers of alpha(1)-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysemaAm J Respir Cell Mol Biol200226672373012034572
  • HubbardRCSellersSCzerskiDStephensLCrystalRGBiochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiencyJAMA19882609125912643261353
  • American Thoracic Society; European Respiratory SocietyAmerican Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiencyAm J Respir Crit Care Med2003168781890014522813
  • SilvermanEKSandhausRAClinical practice. Alpha1-antitrypsin deficiencyN Engl J Med2009360262749275719553648
  • SeersholmNWenckerMBanikNDoes alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study groupEur Respir J19971010226022639387950
  • WenckerMFuhrmannBBanikNKonietzkoNLongitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitorChest2001119373774411243951
  • LiebermanJAugmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting dataChest200011851480148511083705
  • DirksenADijkmanJHMadsenFA randomized clinical trial of alpha(1)-antitrypsin augmentation therapyAm J Respir Crit Care Med19991605 Pt 11468147210556107
  • DirksenAPiitulainenEParrDGExploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiencyEur Respir J20093361345135319196813
  • KueppersFThe role of augmentation therapy in alpha-1 antitrypsin deficiencyCurr Med Res Opin201127357958821226542
  • CazzolaMMacNeeWMartinezFJOutcomes for COPD pharmacological trials: from lung function to biomarkersEur Respir J2008312416e6918238951
  • HorvathIHuntJBarnesPJExhaled breath condensate: methodological recommendations and unresolved questionsEur Respir J200526352354816135737
  • KoczullaARNoeskeSHerrCAmbient temperature impacts on pH of exhaled breath condensateRespirology201015115515919947991
  • SackUScheibeRWotzelMMultiplex analysis of cytokines in exhaled breath condensateCytometry A200669316917216496377
  • MirandaEPerezJEkeowaUIA novel monoclonal antibody to characterize pathogenic polymers in liver disease associated with alpha1-antitrypsin deficiencyHepatology20105231078108820583215
  • BalsRBeisswengerCBlouquitSChinetTIsolation and air-liquid interface culture of human large airway and bronchiolar epithelial cellsJ Cyst Fibros20043Suppl 2495115463925
  • JanciauskieneSZelvyteIJanssonLStevensTDivergent effects of alpha1-antitrypsin on neutrophil activation, in vitroBiochem Biophys Res Commun2004315228829614766206
  • SurhoneLMTimpledonMTMarsekenSFNormality Test: Data Set, Normal Distribution, Random Variable, Model Selection, Interpretations of ProbabilityBetascript Publishing2010
  • DickensJALomasDAWhy has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesisDrug Des Devel Ther20115391405
  • StockleyRABayleyDLUnsalIDowsonLJThe effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiencyAm J Respir Crit Care Med2002165111494149812045122
  • KasaharaYTuderRMTaraseviciene-StewartLInhibition of VEGF receptors causes lung cell apoptosis and emphysemaJ Clin Invest2000106111311131911104784
  • NitaIHollanderCWestinUJanciauskieneSMProlastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine releaseRespir Res200561215683545
  • GadekJEKleinHGHollandPVCrystalRGReplacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjectsJ Clin Invest1981685115811657028785
  • LomasDAElliottPRCarrellRWCommercial plasma alpha1-antitrypsin (Prolastin) contains a conformationally inactive, latent componentEur Respir J19971036726759073003
  • BoringLGoslingJChensueSWImpaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout miceJ Clin Invest199710010255225619366570
  • BaggioliniMClark-LewisIInterleukin-8, a chemotactic and inflammatory cytokineFEBS Lett19923071971011639201
  • CapocciaBJGregoryADLinkDCRecruitment of the inflammatory subset of monocytes to sites of ischemia induces angiogenesis in a monocyte chemoattractant protein-1-dependent fashionJ Leukoc Biol200884376076818550788
  • MorimotoHHiroseMTakahashiMMCP-1 induces cardioprotection against ischaemia/reperfusion injury: role of reactive oxygen speciesCardiovasc Res200878355456218267955
  • RouhaniFPaoneGSmithNKKreinPBarnesPBrantlyMLLung neutrophil burden correlates with increased pro-inflammatory cytokines and decreased lung function in individuals with alpha(1)-antitrypsin deficiencyChest20001175 Suppl 1250S251S10843938
  • BouttenADehouxMSSetaNCompartmentalized IL-8 and elastase release within the human lung in unilateral pneumoniaAm J Respir Crit Care Med199615313363428542140
  • JanciauskieneSLarssonSLarssonPVirtalaRJanssonLStevensTInhibition of lipopolysaccharide-mediated human monocyte activation, in vitro, by alpha1-antitrypsinBiochem Biophys Res Commun2004321359260015358147
  • PottGBChanEDDinarelloCAShapiroLAlpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole bloodJ Leukoc Biol200985588689519197072
  • BerginDAReevesEPMeleadyP?-1 antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8J Clin Invest2010120124236425021060150
  • SapeyEStockleyJAGreenwoodHBehavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med201118391176118621257786